Natera director-linked trusts sell 1,500 shares

Natera, Inc. director and co-founder Sheena Jonathan reported pre-planned sales of company stock by family trusts.

Rhea-AI Filing Summary

Natera, Inc. director and co-founder Sheena Jonathan reported pre-planned sales of company stock by family trusts. On June 17, 2026, Caraluna 1 and Caraluna 2 Trusts together sold 1,500 shares of Natera common stock in a series of open-market transactions under a Rule 10b5-1 trading plan adopted on June 7, 2024. The sales were executed at weighted average prices around the low- to mid-$220 per share range, based on multiple trades within narrow price bands. After these transactions, Jonathan continues to report 249,352 shares held directly, while Caraluna 1 Trust holds 19,276 shares and Caraluna 2 Trust holds 19,265 shares. The filing notes the trusts hold shares for their beneficiaries and that Jonathan disclaims beneficial ownership of the trust-held securities.

Insider Trade Summary 10b5-1

Net Seller: 1,500 shares

Net Sell 10 txns

Insider Sheena Jonathan

Role Director

Sold 1,500 shs ($330K)

Type	Security	Shares	Price	Value
Sale	Common Stock	256	$218.1371	$56K
Sale	Common Stock	128	$219.2576	$28K
Sale	Common Stock	122	$220.9254	$27K
Sale	Common Stock	244	$221.4641	$54K
Sale	Common Stock	267	$218.1752	$58K
Sale	Common Stock	96	$219.1321	$21K
Sale	Common Stock	71	$220.4632	$16K
Sale	Common Stock	301	$221.3855	$67K
Sale	Common Stock	15	$222.144	$3K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 18,782 shares (Indirect, By Caraluna 1 Trust); Common Stock — 18,782 shares (Indirect, By Caraluna 2 Trust); Common Stock — 249,352 shares (Direct)

Footnotes (11)

1. F1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.74 to $218.56 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.88 to $219.85 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.26 to $221.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.26 to $222.05 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.73 to $218.68 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. F8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.75 to $219.37 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. F9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.94 to $220.87 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
10. F10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.10 to $221.93 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
11. F11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222,03 to $222.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 1,500 shares Example sale price: $222.1440 per share Direct holdings: 249,352 shares +5 more

8 metrics

Shares sold 1,500 shares Total common shares sold on June 17, 2026

Example sale price $222.1440 per share Weighted average price for one reported sale block

Direct holdings 249,352 shares Shares reported as held directly after transactions

Caraluna 1 Trust holdings 19,276 shares Common stock held by Caraluna 1 Trust after sales

Caraluna 2 Trust holdings 19,265 shares Common stock held by Caraluna 2 Trust after sales

Net insider share change -1,500 shares Net effect of reported buy/sell activity (net-sell)

Number of sale transactions 9 transactions Open-market sale entries coded “S” on Form 4

10b5-1 plan adoption date June 7, 2024 Date the pre-arranged trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, beneficial ownership, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership regulatory

"The Reporting Person disclaims beneficial ownership over such securities."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type: "non-derivative" for the common stock sales"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Natera (NTRA) report for Sheena Jonathan?

Natera reported that trusts associated with director and co-founder Sheena Jonathan sold 1,500 shares of common stock. The transactions were open-market sales executed on June 17, 2026, and reported on a Form 4 insider trading filing with the SEC.

How many Natera (NTRA) shares were sold and at what prices?

The trusts sold a total of 1,500 Natera common shares. Weighted average sale prices for the individual trades were around the low- to mid-$220s per share, with specific price ranges disclosed in the filing’s detailed footnotes for each transaction grouping.

Were the Natera (NTRA) insider share sales pre-planned?

Yes. The filing states the share sales were made under a Rule 10b5-1 trading plan adopted on June 7, 2024. Such plans pre-schedule trades, making them more routine and less tied to day-to-day market or company-specific news.

Does Sheena Jonathan still hold Natera (NTRA) shares after these transactions?

Yes. After the reported sales, Sheena Jonathan reports 249,352 Natera shares held directly. In addition, Caraluna 1 Trust holds 19,276 shares and Caraluna 2 Trust holds 19,265 shares, providing context on her associated holdings following the June 17, 2026 trades.

Who actually owns the Natera (NTRA) shares sold by the Caraluna trusts?

The filing explains the Caraluna trusts hold shares for the benefit of their beneficiaries. It also states that Sheena Jonathan disclaims beneficial ownership of the securities held by these trusts, even though she must report their transactions on the Form 4.

What kind of transaction code appears in the Natera (NTRA) Form 4?

The sales are coded with transaction code “S,” which indicates open-market or private sales of non-derivative common stock. There are no option exercises or derivative transactions reported in this Form 4, only common stock sales and a holding entry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 09:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sheena Jonathan

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TEXAS 78753

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			CO-FOUNDER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								249,352	D
Common Stock	06/17/2026		S		256(1)	D	$218.1371(2)	19,276	I	By Caraluna 1 Trust(3)
Common Stock	06/17/2026		S		128(1)	D	$219.2576(4)	19,148	I	By Caraluna 1 Trust(3)
Common Stock	06/17/2026		S		122(1)	D	$220.9254(5)	19,026	I	By Caraluna 1 Trust(3)
Common Stock	06/17/2026		S		244(1)	D	$221.4641(6)	18,782	I	By Caraluna 1 Trust(3)
Common Stock	06/17/2026		S		267(1)	D	$218.1752(7)	19,265	I	By Caraluna 2 Trust(3)
Common Stock	06/17/2026		S		96(1)	D	$219.1321(8)	19,169	I	By Caraluna 2 Trust(3)
Common Stock	06/17/2026		S		71(1)	D	$220.4632(9)	19,098	I	By Caraluna 2 Trust(3)
Common Stock	06/17/2026		S		301(1)	D	$221.3855(10)	18,797	I	By Caraluna 2 Trust(3)
Common Stock	06/17/2026		S		15(1)	D	$222.144(11)	18,782	I	By Caraluna 2 Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.74 to $218.56 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.88 to $219.85 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.26 to $221.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.26 to $222.05 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.73 to $218.68 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.75 to $219.37 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.94 to $220.87 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.10 to $221.93 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222,03 to $222.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Tami Chen, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)